Table 4.
Incidence of Non–Small-Cell Lung Cancer by Tumor Stage and Grade
| Characteristic | Placebo, n (% Per Year) | E+P, n (% Per Year) | Hazard Ratio (95% CI) | P |
|---|---|---|---|---|
| Non-Small-Cell Lung Cancer Histology | ||||
| Adenocarcinoma | 60 (0.05) | 73 (0.06) | 1.17 (0.83–1.64) | .47 |
| Squamous cell | 32 (0.03) | 28 (0.02) | 0.84 (0.50–1.39) | .33 |
| Large cell/neuroendocrine | 10 (0.01) | 15 (0.01) | 1.46 (0.66–3.26) | .35 |
| Unspecified | 23 (0.02) | 44 (0.04) | 1.82 (1.10–3.01) | .05 |
| Non-Small-Cell Lung Cancer Stage | ||||
| Local | 28 (0.03) | 29 (0.03) | 1.00 (0.59–1.68) | .99 |
| Regional | 29 (0.03) | 38 (0.03) | 1.26 (0.77–2.04) | .35 |
| Distant metastases | 47 (0.04) | 67 (0.06) | 1.35 (0.93–1.97) | .11 |
| Non-Small-Cell Lung Cancer Grade | ||||
| Well differentiated | 12 (0.01) | 12 (0.01) | 0.99 (0.44–2.20) | .97 |
| Moderately differentiated | 27 (0.02) | 26 (0.02) | 0.92 (0.54–1.57) | .75 |
| Poorly differentiated | 24 (0.02) | 43 (0.04) | 1.72 (1.04–2.83) | .03 |
| Anaplastic | 7 (0.01) | 5 (<0.01) | 0.67 (0.21–2.12) | .50 |
Stratified by age group at randomization, history of lung cancer, and randomization assignment in dietary modification trial.